The results of two large-scale studies demonstrate that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly reduce the risk of kidney disease progression, hospitalization, and death in ...
In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results